SCHEMBL368516

SCHEMBL368516

CN(C)C(=O)[C@H]1CCCC(N(NC(=O)C(=O)Nc2ccc(Cl)cn2)C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
F10 P00742 4/20 0.41
F2 P00734 1/20 0.41
F5 P12259 1/20 0.41
USP30 Q70CQ3 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
PTK2 Q05397 1/20 0.36
IDO1 P14902 2/20 0.35
VNN1 O95497 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDO2 P48775 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715127 1.00 L3MBTL1 (0.43) L3MBTL1F10F2F5USP30
SCHEMBL4260523 0.92 L3MBTL1 (0.41) L3MBTL1F10F2F5USP30
SCHEMBL4356471 0.91 L3MBTL1 (0.41) L3MBTL1F10F2F5USP30
SCHEMBL4267279 0.90 L3MBTL1 (0.43) L3MBTL1USP30SMN1; SMN2PTK2IDO1
SCHEMBL4268700 0.88 L3MBTL1 (0.41) L3MBTL1USP30SMN1; SMN2PTK2IDO1
SCHEMBL1503995 0.87 L3MBTL1 (0.44) L3MBTL1F10F2F5USP30
SCHEMBL3306854 0.84 USP30 (0.41) L3MBTL1USP30SMN1; SMN2PTK2IDO1
SCHEMBL3306039 0.83 L3MBTL1 (0.38) L3MBTL1USP30SMN1; SMN2PTK2IDO1
SCHEMBL3307770 0.83 L3MBTL1 (0.38) L3MBTL1F10USP30SMN1; SMN2PTK2
SCHEMBL3309223 0.82 L3MBTL1 (0.41) L3MBTL1USP30SMN1; SMN2PTK2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024197723-A1 PREPARATION METHOD FOR EDOXABAN TOSILATE 浙江九洲药业股份有限公司 2024-10-03 WO disclosed
US-9447118-B2 Preparation method of optically active diamine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-20 US disclosed
US-20160016974-A1 PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-21 US disclosed
EP-2407457-A1 PROCESS FOR PRODUCING DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-01-18 EP disclosed
EP-2407450-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-01-18 EP disclosed
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM DAIICHI PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
US-7576135-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 L3MBTL1 985/4885F10 9/4885F2 1/4885
US-20160016974-A1 PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND F12, F8, F11 L3MBTL1 4199/4885F10 12/4885F2 5/4885
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM C1R, C9, F2 L3MBTL1 1605/4885F10 127/4885F2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.